{"id":698,"date":"2023-01-31T15:50:03","date_gmt":"2023-01-31T15:50:03","guid":{"rendered":"https:\/\/healthnews.zone\/?p=698"},"modified":"2023-01-31T15:50:03","modified_gmt":"2023-01-31T15:50:03","slug":"personalized-melanoma-vaccines-prolong-survival-in-largest-trial-yet","status":"publish","type":"post","link":"https:\/\/healthnews.zone\/?p=698","title":{"rendered":"Personalized melanoma vaccines prolong survival in largest trial yet"},"content":{"rendered":"\n<p>People who received a personalized melanoma skin cancer vaccine on top of a standard treatment were less likely to die over the study period than those who had the standard treatment alone<\/p>\n\n\n\n<p>Custom-made cancer vaccines that prime an individual\u2019s immune system to attack the unique biology of their tumor have halted the progression of melanoma skin cancer in almost half the people taking part in a randomized clinical trial.<\/p>\n\n\n\n<p>Continued Article: <a href=\"https:\/\/www.newscientist.com\/article\/2351872-personalised-melanoma-vaccines-prolong-survival-in-largest-trial-yet\/\">https:\/\/www.newscientist.com\/article\/2351872-personalised-melanoma-vaccines-prolong-survival-in-largest-trial-yet\/<\/a><\/p>\n\n\n\n<p><a rel=\"noreferrer noopener\" href=\"http:\/\/api.addthis.com\/oexchange\/0.8\/forward\/facebook\/offer?pubid=ns.html&amp;url=https:\/\/www.newscientist.com\/article\/2351872-personalised-melanoma-vaccines-prolong-survival-in-largest-trial-yet\/&amp;title=Personalised%20melanoma%20vaccines%20prolong%20survival%20in%20largest%20trial%20yet&amp;description=People%20who%20received%20a%20personalised%20melanoma%20skin%20cancer%20vaccine%20on%20top%20of%20a%20standard%20treatment%20were%20less%20likely%20to%20die%20over%20the%20study%20period%20than%20those%20who%20had%20the%20standard%20treatment%20alone\" target=\"_blank\"><\/a><a rel=\"noreferrer noopener\" href=\"http:\/\/api.addthis.com\/oexchange\/0.8\/forward\/twitter\/offer?pubid=ns.html&amp;url=https:\/\/www.newscientist.com\/article\/2351872-personalised-melanoma-vaccines-prolong-survival-in-largest-trial-yet\/&amp;title=Personalised%20melanoma%20vaccines%20prolong%20survival%20in%20largest%20trial%20yet&amp;description=People%20who%20received%20a%20personalised%20melanoma%20skin%20cancer%20vaccine%20on%20top%20of%20a%20standard%20treatment%20were%20less%20likely%20to%20die%20over%20the%20study%20period%20than%20those%20who%20had%20the%20standard%20treatment%20alone\" target=\"_blank\"><\/a><a rel=\"noreferrer noopener\" href=\"http:\/\/api.addthis.com\/oexchange\/0.8\/forward\/whatsapp\/offer?pubid=ns.html&amp;url=https:\/\/www.newscientist.com\/article\/2351872-personalised-melanoma-vaccines-prolong-survival-in-largest-trial-yet\/&amp;title=Personalised%20melanoma%20vaccines%20prolong%20survival%20in%20largest%20trial%20yet&amp;description=People%20who%20received%20a%20personalised%20melanoma%20skin%20cancer%20vaccine%20on%20top%20of%20a%20standard%20treatment%20were%20less%20likely%20to%20die%20over%20the%20study%20period%20than%20those%20who%20had%20the%20standard%20treatment%20alone\" target=\"_blank\"><\/a><a rel=\"noreferrer noopener\" href=\"http:\/\/api.addthis.com\/oexchange\/0.8\/forward\/linkedin\/offer?pubid=ns.html&amp;url=https:\/\/www.newscientist.com\/article\/2351872-personalised-melanoma-vaccines-prolong-survival-in-largest-trial-yet\/&amp;title=Personalised%20melanoma%20vaccines%20prolong%20survival%20in%20largest%20trial%20yet&amp;description=People%20who%20received%20a%20personalised%20melanoma%20skin%20cancer%20vaccine%20on%20top%20of%20a%20standard%20treatment%20were%20less%20likely%20to%20die%20over%20the%20study%20period%20than%20those%20who%20had%20the%20standard%20treatment%20alone\" target=\"_blank\"><\/a><a rel=\"noreferrer noopener\" href=\"http:\/\/api.addthis.com\/oexchange\/0.8\/forward\/reddit\/offer?pubid=ns.html&amp;url=https:\/\/www.newscientist.com\/article\/2351872-personalised-melanoma-vaccines-prolong-survival-in-largest-trial-yet\/&amp;title=Personalised%20melanoma%20vaccines%20prolong%20survival%20in%20largest%20trial%20yet&amp;description=People%20who%20received%20a%20personalised%20melanoma%20skin%20cancer%20vaccine%20on%20top%20of%20a%20standard%20treatment%20were%20less%20likely%20to%20die%20over%20the%20study%20period%20than%20those%20who%20had%20the%20standard%20treatment%20alone\" target=\"_blank\"><\/a><a rel=\"noreferrer noopener\" href=\"mailto:?subject=Personalised%20melanoma%20vaccines%20prolong%20survival%20in%20largest%20trial%20yet&amp;body=People%20who%20received%20a%20personalised%20melanoma%20skin%20cancer%20vaccine%20on%20top%20of%20a%20standard%20treatment%20were%20less%20likely%20to%20die%20over%20the%20study%20period%20than%20those%20who%20had%20the%20standard%20treatment%20alone%0D%0Aread%20more:%20https:\/\/www.newscientist.com\/article\/2351872-personalised-melanoma-vaccines-prolong-survival-in-largest-trial-yet\/\" target=\"_blank\"><\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>People who received a personalized melanoma skin cancer vaccine on top of a standard treatment were less likely to die over the study period than those who had the standard treatment alone Custom-made cancer vaccines that prime an individual\u2019s immune system to attack the unique biology of their tumor have halted the progression of melanoma skin cancer in almost half the people taking part in a randomized clinical trial. Continued Article: https:\/\/www.newscientist.com\/article\/2351872-personalised-melanoma-vaccines-prolong-survival-in-largest-trial-yet\/<\/p>\n","protected":false},"author":4,"featured_media":0,"comment_status":"open","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[15],"tags":[],"class_list":["post-698","post","type-post","status-publish","format-standard","hentry","category-cancer-research"],"_links":{"self":[{"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/posts\/698","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/users\/4"}],"replies":[{"embeddable":true,"href":"https:\/\/healthnews.zone\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=698"}],"version-history":[{"count":1,"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/posts\/698\/revisions"}],"predecessor-version":[{"id":699,"href":"https:\/\/healthnews.zone\/index.php?rest_route=\/wp\/v2\/posts\/698\/revisions\/699"}],"wp:attachment":[{"href":"https:\/\/healthnews.zone\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=698"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/healthnews.zone\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=698"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/healthnews.zone\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=698"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}